In over 90% of lung cancers, the cell cycle occurs as dysregulation, which makes the derangements of cell cycle mediators in the expression and/or activation, especially within the CDK–cyclin–RB pathways, and is integrally involved in malignant transformation and tumor progression, destroying the cell proliferation mechanism controlling the growth of advanced NSCLC (3–5). Here, RB1 is linked to lung cancer.